11:02 AM EST, 03/03/2025 (MT Newswires) -- Spectral Medical ( EDTXF ) on Monday said it is nearing the end patient enrollment for its Tigris trial, a Phase 3 follow-on study evaluating Polymyxin B Hemoperfusion (PMX) in a trial of adults treated for endotoxemia and septic shock.

The company said 152 patients are enrolled to date, with six patients signed on in February. Spectral estimates it will require a further four to seven patients (given the enrollment randomization scheme) to reach 150 "evaluable" patients.

Full enrollment for the project will be achieved closer to the end of this month.

"We are very much in the final stretch of enrollment into Tigris, which we attribute to continued strong activity and engagement at our Tigris sites. As such, we remain confident in finalizing full Tigris enrollment closer to the end of the first quarter in 2025," said John Kellum, Chief Medical Officer.

Spectral was last seen up $0.01 to $0.74 on the Toronto Stock Exchange.

Price: 0.74, Change: +0.01, Percent Change: +1.37